Worldwide revenue of $372.8 million in the first quarter 2025 GAAP fully diluted earnings per share of $1.02, compared to $1.87 in the first quarter of 2024; adjusted fully diluted earnings per share of $1.53, compared to $1.69 in the first quarter of 2024 Free cash flow totaled $98.8 million for the first quarter 2025 Closed acquisition of Evergreen Theragnostics early in the second quarter; expect to close on acquisition... Read More

Enables Lantheus to focus on innovative radiopharmaceuticals, while maximizing the value of its SPECT business SHINE will acquire products TechneLite ® , NEUROLITE ® , Xenon Xe-133 Gas, and Cardiolite ® BEDFORD, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ( “Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow... Read More

BEDFORD, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that its clinical-stage F18-labeled tau Positron Emission Tomography (PET) radiodiagnostic, MK-6240 (F18-florquinitau), successfully met its co-primary... Read More

BEDFORD, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, May 7, 2025, to discuss its financial and operating results for the first quarter of 2025. To access the conference call or webcast, participants should register online at... Read More

BEDFORD, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that it has completed its previously announced acquisition of Evergreen Theragnostics, Inc. (“Evergreen”), a clinical-stage... Read More

Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024 Free cash flow was $141.4 million and $493.1 million for the fourth quarter and full year 2024 GAAP fully diluted loss per share of $(0.17) and earnings per share of $4.36 for the fourth quarter and full year 2024 Adjusted fully diluted earnings per share of $1.59 and $6.76 for the fourth quarter and full year 2024 PYLARIFY... Read More

BEDFORD, Mass., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced members of its management team will present at the following upcoming investor conferences. B. Riley Securities Precision Oncology & Radiopharma Day in New... Read More

BEDFORD, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, February 26, 2025, to discuss its financial and operating results for the fourth quarter and full year of 2024. To access the conference call or webcast, participants should register online at... Read More

Data highlights PYLARIFY’s ability to detect recurrent prostate cancer in patients with low PSA Real-world evidence of PYLARIFY’s effectiveness in prostate cancer being presented BEDFORD, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient... Read More

BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D. to Lantheus’ Board of Directors (“Board”), effective February 1, 2025. Dr. Morrow is an experienced... Read More

Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities Adds OCTEVY™, a registrational-stage diagnostic asset, targeting neuroendocrine tumors that is complementary to Lantheus’ therapeutic agent, PNT2003 Expands oncology radiopharmaceutical pipeline with multiple clinical and pre-clinical theranostic pairs Company reaffirms Full-Year and... Read More

Enhances Lantheus’ growth profile with Neuraceq ® , a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer’s Disease Advances Lantheus’ radiopharmaceutical leadership with addition of Alzheimer’s radiodiagnostic commercial infrastructure, expanded pipeline, and enhanced R&D capabilities Transaction expected to be accretive to adjusted EPS within the first 12 months... Read More

BEDFORD, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announces that its board of directors has authorized a program to repurchase up to $250 million of its common stock during the next twelve months. “With our... Read More

BEDFORD, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Bob Marshall, Chief Financial Officer and Treasurer, will present at the Jefferies London Healthcare Conference at 1:00 p.m. GMT (8 a.m. EST) on Wednesday,... Read More

BEDFORD, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, notes that the Centers for Medicare & Medicaid Services (CMS) recently posted updated payment rates in Addendum B related to the final rule for the calendar... Read More

Worldwide revenue of $378.7 million, an increase of 18.4% from third quarter 2023 GAAP fully diluted earnings per share of $1.79, compared to $1.88 in the third quarter of 2023. Adjusted fully diluted earnings per share of $1.70 compared to $1.47 in the third quarter of 2023 Company narrows full year 2024 revenue and fully diluted earnings per share guidance towards higher end of the previously issued guidance Company... Read More

BEDFORD, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, applauds the Centers for Medicare & Medicaid Services’ (CMS) final rule for the calendar year 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS). The rule,... Read More

BEDFORD, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, November 6, 2024, to discuss its financial and operating results for the third quarter of 2024. To access the conference call or webcast, participants should register online at... Read More

Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3% Complete Responses Patients demonstrated statistically significant improvement in time to reduction of health-related quality of life (HRQoL) as measured by Functional Assessment of Cancer Therapy—Prostate (FACT-P) Interim Overall... Read More

BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus’ Board of Directors (“Board”), effective as of September... Read More

BEDFORD, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the Morgan Stanley 22 nd Annual Global Healthcare Conference at 7:45 a.m. ET on Wednesday, September... Read More

BEDFORD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that Oliver Sartor, MD, Director of Radiopharmaceutical Trials and Professor of Medical Oncology at the Mayo Clinic in Rochester, Minnesota, will deliver an... Read More

Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023 Completed three strategic transactions to expand innovative pipeline GAAP fully diluted earnings per share of $0.88, compared to $1.33 in second quarter 2023. Adjusted fully diluted earnings per share of $1.80 compared to $1.54 in the second quarter 2023, reflective of inter-quarter investment in business development and... Read More

BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 31, 2024, to discuss its financial and operating results for the second quarter of 2024. To access the conference call or webcast, participants should register online at... Read More

BEDFORD, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced its acquisition of Meilleur Technologies, Inc., which includes NAV-4694, expanding Lantheus’ Alzheimer’s disease pipeline. Through this acquisition, Lantheus... Read More

BEDFORD, Mass., July 10, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced that it welcomes the Centers for Medicare & Medicaid Services’ (CMS’) Proposed Medicare Hospital Outpatient Prospective Payment System (OPPS) Rule for calendar year... Read More

BEDFORD, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Jamie Spaeth to its Executive Team as Chief People Officer. “We’re excited to have Jamie join Lantheus as we continue to harness our team’s... Read More

BEDFORD, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced its acquisition of the global rights of Life Molecular Imaging’s (“Life Molecular”) RM2, targeting the gastrin-releasing peptide receptor (GRPR), including... Read More

Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in Radiopharm Offer price for the shares of A$0.05 represents a 47% premium to the last closing price of $0.034 on 19 June 2024 Option for Lantheus to invest a further A$7.5m within 6 months on the same terms Lantheus will also secure rights to two early preclinical assets in exchange for an A$3m upfront payment pursuant to a transfer and... Read More

BEDFORD, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that aPROMISE, its AI-enabled FDA-cleared medical device software, is now available on the syngo .via platform, from Siemens Healthineers, one of the leading... Read More

BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Paul Blanchfield, President, will present at the William Blair 44th Annual Growth Stock Conference at 2:40 p.m. CT on Tuesday, June 4. To access a live webcast... Read More

Jeffrey S. Humphrey, MD appointed Chief Medical Officer; Jean-Claude Provost, MD named Chief Science Officer BEDFORD, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Jeffrey S. Humphrey, MD has been appointed Chief... Read More

First Quarter 2024 Worldwide revenue of $370.0 million, an increase of 23.0% from first quarter 2023 GAAP fully diluted net income per share of $1.87, compared to GAAP fully diluted net loss per share of $0.04 in first quarter 2023. Adjusted fully diluted net income per share of $1.69 compared to adjusted fully diluted net income per share of $1.47 in the first quarter 2023 The Company increases full year 2024 net revenue... Read More

BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024, to discuss its financial and operating results for the first quarter of 2024. To access the conference call or webcast, participants should register online at... Read More

BEDFORD, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Paul Blanchfield, President, will present at the Leerink Partners Global Biopharma Conference 2024 at 9:20 a.m. ET on Tuesday, March 12. To access a live... Read More

BEDFORD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc . (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow ® disease to deliver better patient outcomes, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for DEFINITY ® (Perflutren Lipid Microsphere)... Read More

BEDFORD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the promotion of Amanda Morgan to Chief Commercial Officer and her elevation to be a member of the company’s Executive Team, effective March 25, 2024. In her... Read More

BEDFORD, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Paul Blanchfield, President, will present at the TD Cowen 44th Annual Health Care Conference at 10:30 a.m. ET on Monday, March 4. To access a live webcast of... Read More

Worldwide revenue of $354.0 million and $1.3 billion for the fourth quarter and full year 2023 GAAP net income of $103.4 million and $326.7 million for the fourth quarter and full year 2023 GAAP fully diluted net income per share of $1.47 and $4.65 for the fourth quarter and full year 2023 Adjusted fully diluted net income per share of $1.75 and $6.23 for the fourth quarter and full year 2023 Net cash provided by operating... Read More

Lantheus to supply MK-6240, an investigational F18-labeled PET imaging agent that targets tau tangles BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced a collaboration agreement with a National Institute on... Read More

BEDFORD, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, February 22, 2024, to discuss its financial and operating results for the fourth quarter and full year of 2023. To access the conference call or webcast, participants should register online at... Read More

Lantheus Board Member and Pharmaceutical Industry Veteran Brian Markison Appointed Lantheus Chief Executive Officer, Effective March 1, 2024 Mary Anne Heino to Retire as Chief Executive Officer and Become Chair of the Board of Directors BEDFORD, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to... Read More

BEDFORD, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that its Abbreviated New Drug Application (ANDA) for Lutetium Lu 177 Dotatate ( 177 Lu-PNT2003), a generic version of LUTATHERA ® (lutetium... Read More

Option to license Perspective Therapeutics’ Pb212-VMT-α-NET asset Co-development rights for certain Pb212-based alpha therapies for prostate cancer Equity investment of up to 19.9% in Perspective Therapeutics Perspective Therapeutics intends to acquire Somerset, NJ radiopharmaceutical manufacturing facility BEDFORD, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH) today announced it... Read More

Full year 2023 worldwide revenue expected to be in the range of $1.295 – 1.297 billion, a 38 - 39% increase over the prior year including a $15 million RELISTOR milestone achievement Full year 2023 PYLARIFY revenue expected to be in the range of $851 - 853 million, pending final partner reconciliation, an increase of 61 - 62% over the prior year Full year 2023 DEFINITY revenue expected to be approximately $279 million, a 14%... Read More

BEDFORD, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Mary Anne Heino, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference at 11:15 a.m. PST on Wednesday, January 10. To... Read More

BEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes,, today announced Paul Blanchfield, President, and Bob Marshall, Chief Financial Officer and Treasurer, will present at the Jefferies London Healthcare Conference at 8:00 a.m.... Read More

Worldwide revenue of $319.9 million for the third quarter 2023, representing an increase of 33.7% from the prior year period GAAP net income of $132.0 million for the third quarter 2023, compared to GAAP net income of $61.2 million in the prior year period GAAP fully diluted net income per share of $1.88 for the third quarter 2023, compared to GAAP fully diluted net income per share of $0.86 in the prior year period;... Read More

BEDFORD, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 2, 2023, to discuss its financial and operating results for the third quarter of 2023. To access the conference call or webcast, participants should register online at... Read More

BEDFORD, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced PYLARIFY AI data will be presented at the upcoming 2023 European Association of Nuclear Medicine (EANM) Annual Meeting, which... Read More

BEDFORD, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced Paul Blanchfield, President, and Bob Marshall, Chief Financial Officer and Treasurer, will present at the Wells Fargo... Read More

BEDFORD, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced the divestiture of its RELISTOR (methylnaltrexone bromide) net sales royalties. The sale of this non-core... Read More

Worldwide revenue of $321.7 million for the second quarter 2023, representing an increase of 43.8% from the prior year period GAAP net income of $94.1 million for the second quarter 2023, compared to GAAP net income of $43.1 million in the prior year period GAAP fully diluted net income per share of $1.33 for the second quarter 2023, compared to GAAP fully diluted net income per share of $0.61 in the prior year period;... Read More

BEDFORD, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 3, 2023, to discuss its financial and operating results for the second quarter of 2023. To access the conference call or webcast, participants should register online at... Read More

BEDFORD, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced it will present the following presentations at the upcoming 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI)... Read More

BEDFORD, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced Mary Anne Heino, Chief Executive Officer, and Bob Marshall, Chief Financial Officer and Treasurer, will present at the... Read More

BEDFORD, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced that it has instructed the rights agent to distribute $99.7 million to the holders of Contingent Value Rights (CVRs), which... Read More

Worldwide revenue of $300.8 million for the first quarter 2023, representing an increase of 44.0% from the prior year period GAAP net loss of $2.8 million for the first quarter 2023, compared to GAAP net income of $43.0 million in the prior year period GAAP fully diluted net loss per share of $.04 for the first quarter 2023, compared to GAAP fully diluted net income per share of $0.61 in the prior year period; adjusted fully... Read More

BEDFORD, Mass. and INDIANAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, and POINT Biopharma Global, Inc. (“POINT”) (NASDAQ: PNT), a company accelerating the discovery, development and global... Read More

BEDFORD, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc . (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, May 4, 2023, to discuss its financial and operating results for the first quarter of 2023. To access the conference call or webcast, participants should register online at... Read More

BEDFORD, Mass., March 17, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced that Paul Blanchfield has been promoted to President and Dan Niedzwiecki has been promoted to Chief Administrative Officer.... Read More

Worldwide revenue of $263.2 million and $935.1 million for the fourth quarter and full year 2022, representing increases of 103.1% and 119.9% over the prior year periods, respectively GAAP net loss of $119.2 million and GAAP net income of $28.1 million for the fourth quarter and full year 2022, compared to GAAP net loss of $40.2 million and $71.3 million in the prior year period GAAP fully diluted net loss per share of $1.74... Read More

BEDFORD, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today presented piflufolastat F 18 data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking... Read More

BEDFORD, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, February 23, 2023, to discuss its financial and operating results for the fourth quarter and full year of 2022. To access the conference call or webcast, participants should register online at... Read More

BEDFORD, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced it will present piflufolastat F 18 data at the upcoming 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers... Read More

BEDFORD, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced it has acquired Knoxville-based Cerveau Technologies, Inc. (“Cerveau”). Cerveau’s asset is MK-6240, a second-generation F... Read More

NORTH BILLERICA, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced Mary Anne Heino, President and Chief Executive Officer, will present at the J.P. Morgan 2023 Healthcare... Read More

NORTH BILLERICA, Mass., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced the closing of the strategic collaboration agreements previously announced on November 14, 2022 between Lantheus and... Read More